Literature DB >> 21817183

Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding.

Michelle Giles1, Kumar Visvanathan, Joe Sasadeusz.   

Abstract

It is estimated there are 350-400 million people worldwide chronically infected with HBV. Many of these are women and of reproductive age. As such, they may face therapeutic decisions regarding antiviral therapy and the implication this may have on future or current pregnancies. This article reviews the data of all antivirals licensed for use against hepatitis B infection regarding teratogenicity, carcinogenicity, clinical experience during pregnancy, placental transfer and excretion in breast milk.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21817183     DOI： 10.3851/IMP1813

Source DB:  PubMed          Journal:  Antivir Ther        ISSN： 1359-6535


  10 in total

1.  Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection.

Authors:  Mustafa Kemal Celen; Duygu Mert; Müzeyyen Ay; Tuba Dal; Safak Kaya; Necmettin Yildirim; Serda Gulsun; Tunga Barcin; Sevgi Kalkanli; Mehmet Sinan Dal; Celal Ayaz
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 2.  Chronic hepatitis B virus infection and pregnancy.

Authors:  Manoj Kumar; Tarandeep Singh; Swati Sinha
Journal:  J Clin Exp Hepatol       Date:  2012-09-20

Review 3.  Gender specific medicine in liver diseases: a point of view.

Authors:  Marilena Durazzo; Paola Belci; Alessandro Collo; Vanessa Prandi; Erika Pistone; Maria Martorana; Roberto Gambino; Simona Bo
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

4.  Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series.

Authors:  Calvin Q Pan; Li-Jun Mi; Chalermrat Bunchorntavakul; Jeffrey Karsdon; William M Huang; Gaurav Singhvi; Marc G Ghany; K Rajender Reddy
Journal:  Dig Dis Sci       Date:  2012-04-29       Impact factor: 3.199

Review 5.  Hepatitis B virus infection and pregnancy: a practical approach.

Authors:  Ashish Kumar
Journal:  Indian J Gastroenterol       Date:  2012-04-21

6.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.

Authors:  Yun-Fan Liaw; Jia-Horng Kao; Teerha Piratvisuth; Henry Lik Yuen Chan; Rong-Nan Chien; Chun-Jen Liu; Ed Gane; Stephen Locarnini; Seng-Gee Lim; Kwang-Hyub Han; Deepak Amarapurkar; Graham Cooksley; Wasim Jafri; Rosmawati Mohamed; Jin-Lin Hou; Wan-Long Chuang; Laurentius A Lesmana; Jose D Sollano; Dong-Jin Suh; Masao Omata
Journal:  Hepatol Int       Date:  2012-05-17       Impact factor: 6.047

Review 7.  Roles of Interferons in Pregnant Women with Dengue Infection: Protective or Dangerous Factors.

Authors:  Hao Zhang; Zhiyi He; Wenting Zeng; Hong-Juan Peng
Journal:  Can J Infect Dis Med Microbiol       Date:  2017-09-07       Impact factor: 2.471

8.  Infant immune response to hepatitis B vaccine after fetal exposure to telbivudine.

Authors:  Yandi Li; Wenxin Chen; Cong Jin; Ting Wang; Tian Yao; Shuying Feng; Bo Wang; Yongliang Feng; Suping Wang
Journal:  Hum Vaccin Immunother       Date:  2022-03-16       Impact factor: 3.452

9.  Efficacy and safety of nucleos(t)ide analogues to prevent hepatitis B virus mother-to-child transmission in pregnant women with high viremia: real life practice from China.

Authors:  Qiuju Sheng; Yang Ding; Baijun Li; Chao Han; Yanwei Li; Chong Zhang; Han Bai; Jingyan Wang; Lianrong Zhao; Tingting Xia; Ziying An; Mingxiang Zhang; Xiaoguang Dou
Journal:  Int J Med Sci       Date:  2018-05-22       Impact factor: 3.738

10.  Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System.

Authors:  Renjun Yang; Nuoya Yin; Ying Zhao; Dandan Li; Xuanling Zhang; Xingang Li; Yang Zhang; Francesco Faiola
Journal:  Front Pharmacol       Date:  2022-01-03       Impact factor: 5.810
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.